[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cardiovascular and Interventional Radiological Society of Europe\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,80,104,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100613743","orbital-atherectomy-for-lesion-preparation-in-patients-with-chronic-limb-threatening-ischemia-100613743",false,"NCT07270562","ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia","ORACLE","Inclusion Criteria:\n\n1. Rutherford classification category ≥4;\n2. Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;\n3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;\n4. Patients competent and willing to provide informed consent.\n\nExclusion Criteria:\n\n1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);\n2. Inadequate inflow (\\>30% stenosis) following optimization;\n3. Insufficient direct outflow (less than 1 run-off vessel);\n4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;\n5. Patients planned to receive an above ankle amputation of the target limb;\n6. Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.",[24,25],"Chronic Limb Threatening Ischemia","Chronic Limb-Threatening Ischemia",[27,28,29,30,31,32,33,34,35,36,37,38],"CLTI","Peripheral artery disease","Orbital atherectomy","Observational cohort study","Chronic limb ischemia","Critical limb-threatening ischemia","Calcified peripheral artery lesions","Vessel preparation","Femoropopliteal arteries","Infrapopliteal arteries","OA","Atherectomy for calcified lesions","NOT_YET_RECRUITING","2026-07-01",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":20},"2026-08",{"date":47,"type":20},"2031-12",{"name":49,"class":50},"Cardiovascular and Interventional Radiological Society of Europe","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100613271","bleeding-reduction-in-grade-ii-iii-haemorrhoids-through-embolization-treatment-100613271","NCT07264413","Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment","BRIGHT","Inclusion Criteria:\n\n1. Adult patients presenting bleeding Grade II-III haemorrhoids with French bleeding score ≥3 planned to be treated with HAE using embolization coils;\n2. Patients competent and willing to give written informed consent.\n\nExclusion Criteria:\n\n1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);\n2. Patients receiving HAE using a combination of coils and particles, particles only, or any other embolic agents;\n3. Patients who have had previous surgical haemorrhoidectomy at any time or other treatments for haemorrhoids within 1 year before the planned HAE;\n4. Patients with known perianal sepsis, inflammatory bowel disease, peri-anal fistula, colorectal malignancy or pre-existing sphincter injury resulting in incontinence;\n5. Patients with an immunodeficiency;\n6. Known severe atheromatous disease with occlusion of target vessels preventing embolization;\n7. Absolute contraindication to contrast media;\n8. ECOG performance status \\> 2;\n9. Life expectancy \\\u003C 12 months;\n10. Patients with unstable angina;\n11. Patients currently taking nicorandil.",{"count":19,"type":20},"BRIGHT is a Europe-wide study that will follow up to 250 adults with bleeding symptoms from haemmorhoids (Grade II-III categories). It aims to understand how well a minimally invasive procedure called haemorrhoid artery embolization (HAE) works in everyday clinical practice, which is a technique that blocks the blood vessels feeding the haemorrhoids. As this technique does not require major surgery, HAE offers several benefits such as less trauma, quicker recovery, and the use of only local anaesthesia.",[61,62],"Hemorrhoid","Hemorrhoid Bleeding",[64,65,66,67,68,69,70,71,72,73,74],"Haemorrhoids","Grade II-III haemorrhoids","Symptomatic haemorrhoids","Hemorrhoidal bleeding","Haemorrhoidal disease","Haemorrhoid artery embolization","HAE","Artery embolization","Transarterial embolization","Minimally invasive","Embolization coils",{"date":42,"type":43},{"date":45,"type":20},{"date":78,"type":20},"2030-12",{"name":49,"class":50},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100613744","resorbable-scaffolds-with-everolimus-elution-for-the-treatment-of-infrapopliteal-artery-disease-in-patients-with-chronic-limb-threatening-ischemia-100613744","NCT07270575","REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia","RESCUE","Inclusion Criteria:\n\n1. Rutherford classification category ≥4;\n2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;\n3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;\n4. Patients competent and willing to provide informed consent.\n\nExclusion Criteria:\n\n1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);\n2. Inadequate inflow (\\>30% stenosis) following optimization;\n3. Insufficient direct outflow (less than 1 run-off vessel);\n4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;\n5. Patients planned to receive an above ankle amputation of the target limb;\n6. Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).",{"count":88,"type":20},400,"RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.\n\nThese drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.",[24,25],[27,92,93,28,94,95,96,97,98,33,36],"Critical Limb-Threatening Ischemia","Infrapopliteal artery disease","Esprit BTK Everolimus Eluting Resorbable Scaffold","Drug-eluting resorbable scaffold","Resorbable vascular scaffold","Real-world evidence study","Patients with infrapopliteal disease",{"date":42,"type":43},{"date":45,"type":20},{"date":102,"type":20},"2032-12",{"name":49,"class":50},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100527583","chronic-limb-threatening-ischemia-treated-with-intravascular-lithotripsy-observational-study-100527583","NCT06149650","Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study","CALCIO","Inclusion Criteria:\n\n* Patient with chronic limb-threatening ischemia (Rutherford Category ≥4)\n* Femoropopliteal and\u002For crural calcified lesions visible on fluoroscopy;\n* Treatment with IVl using the Shockwave Medical IVL System.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Endovascular procedure(s) on the treatment site within 4 weeks before the planned IVL treatment.",{"count":88,"type":20},"CALCIO is a multicentre, prospective, observational cohort study that will collect real world data on the use of intravascular Lithotripsy (IVL) with the Shockwave IVL system to disrupt calcified femoropopliteal and crural lesions in patients with chronic limb-threatening ischemia (CLTI). The primary objective of CALCIO is to understand the effectiveness of IVL in promoting wound healing and preventing amputation. The secondary objectives of CALCIO are to evaluate the immediate effectiveness of the treatment in restoring vessel patency as well as its safety and impact on patients' quality of life.",[25],[27],"RECRUITING","2026-05-11",{"date":118,"type":43},"2026-05-13",{"date":120,"type":43},"2024-07-15",{"date":122,"type":20},"2028-12-31",{"name":49,"class":50},39,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":134,"studyType":21,"phases":4,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":5},"100553043","bone-metastases-registry-for-patients-undergoing-cryoablation-with-curative-purpose-100553043","NCT06480955","BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","BOREALIS","Inclusion Criteria:\n\n* Bone metastases in patients with oligometastatic disease (\\\u003C5 bone\u002Fvisceral metastases) or bone oligo-progressive disease (visceral or osseous multi-metastatic disease stable under systemic treatment except 1-3 progressing bone metastases) from solid tumours;\n* Number of target lesions ≤ 3\n* Size of target lesion(s) \\\u003C 5 cm (largest diameter);\n* Referral to local ablative treatment by multidisciplinary tumour board (MDTB);\n* Treatment by percutaneous cryoablation with curative intent (i.e., complete tumour destruction) assessed as technically feasible by the IR in charge;\n* Procedure performed with a cryoablation system from Boston Scientific.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Health status not compatible with the minimum meaningful follow-up period (i.e., 12 months):\n\n  * Karnofsky Performance Scale \\\u003C 60%, or\n  * Bone metastases originating from rapidly evolving tumour histologies not allowing reasonable life expectancy of at least 12 months, or\n  * Life expectancy \\\u003C 12 months\n* Infection of treatment site or systemic infection;\n* Uncorrectable coagulopathy;\n* Haematological disease (including multiple myeloma and plasmacytoma);\n* Concomitant radiation therapy or radiation therapy within 12 weeks before the planned cryoablation procedure.",{"count":133,"type":20},50,"1 Year","BOREALIS is a multicentre, prospective, observational cohort study designed to investigate the effectiveness, feasibility, safety and impact on pain and quality of life of curative-intent cryoablation for the treatment of bone metastases in patients with oligometastatic or bone oligo-progressive disease.",[137],"Bone Metastases",[139,140,141,142],"Cryoablation Oligo-progressive disease","Bone metastases","Oligometastatic Disease","Oligo-progressive disease","2025-12-23",{"date":145,"type":43},"2025-12-30",{"date":147,"type":43},"2025-04-01",{"date":149,"type":20},"2028-04",{"name":49,"class":50},""]